Cargando…
Novel rapid-acting antidepressants: molecular and cellular signaling mechanisms
Depression is a chronic, debilitating, and common illness. Currently available pharmacotherapies can be helpful but have several major drawbacks, including substantial rates of low or no response and a long therapeutic time lag. In pursuit of better treatment options, recent research has focussed on...
Autores principales: | Thomas, Alexandra M., Duman, Ronald S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Portland Press Ltd.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6051536/ https://www.ncbi.nlm.nih.gov/pubmed/30034823 http://dx.doi.org/10.1042/NS20170010 |
Ejemplares similares
-
Molecular and Cellular Mechanisms of Rapid-Acting Antidepressants Ketamine and Scopolamine
por: Wohleb, Eric S., et al.
Publicado: (2017) -
Rapid Acting Antidepressants in Chronic Stress Models: Molecular and Cellular Mechanisms
por: Hare, Brendan D., et al.
Publicado: (2017) -
NMDAR modulators as rapid antidepressants: Converging and distinct signaling mechanisms
por: Lee, Boyoung, et al.
Publicado: (2020) -
Ketamine and rapid-acting antidepressants: a new era in the battle against depression and suicide
por: Duman, Ronald S.
Publicado: (2018) -
Neurobiology of rapid acting antidepressants: convergent effects on GluA1-synaptic function
por: Duman, Ronald S., et al.
Publicado: (2019)